Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus DISPERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus DISPERMOX.
CYCLAPEN-W vs DISPERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic